Arcellx, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.arcellx.com

Moat Score

Market Cap $4.45B
PE -110
Debt $NaN
Cash $164.47M
EV $NaN
FCF $3.58M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$40.42M
EBIT	-$39.24M
ROE	-8%
ROA	-5%
FCF	$3.58M
Equity	$483.02M
Growth Stability	1
PE	-110.01
PB	9.21
P/FCF	1.24K
P/S	28.54
Price/Cash	0.04
Net Margins	-65%
Op. Margins	-25%
Sales Growth YoY	74%
Sales Growth QoQ	-5%
FCF CAGR	-15%
Equity CAGR	39%

Earnings Growth YoY	-34%
Earnings Growth QoQ	-5%
FCF CAGR 5Y	-15%
Equity CAGR 5Y	39%
FCF CAGR 3Y	-30%
Equity CAGR 3Y	41%
Market Cap	$4.45B
Revenue	$155.82M
Assets	$764.91M
Cash	$164.47M
Shares Outstanding	53.33M
Moat Score	4%
Working Capital	450.28M
Current Ratio	4.29
Shares Growth 3y	42%
Equity Growth QoQ	-1%
Equity Growth YoY	81%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

SEC Filings

Direct access to Arcellx, Inc. (ACLX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Arcellx, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Arcellx, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Arcellx, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Arcellx, Inc..

Years

Calculation mode

= $14M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$3.6M	$3.1M	$2.6M	$2.2M	$1.9M	$1.6M	$1.4M	$1.2M	$1M	$871K	$745K	$7.4M
DCF		$2.8M	$2.2M	$1.7M	$1.3M	$1M	$788K	$612K	$476K	$370K	$287K	$2.9M
Value	$14M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-64%	-65%
ROA	-	-60%	-8%	-5%
ROE	-	-92%	-15%	-8%

Bad Net Margins (-65.03%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-
Debt over Equity	-	-	-	-
Growth Stability	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-
Earnings YoY growth	-	190%	-63%	-
Equity YoY growth	-	-269%	137%	39%
FCF YoY growth	-	69%	-283%	-15%